Related Experiment Video

Updated: Mar 18, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer

Joline S J Lim1, Nicholas C Turner1, Timothy A Yap2

  • 1The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom.

Cancer Discovery
|July 3, 2016
PubMed

Insights

Abemaciclib shows promise in treating various advanced solid tumors, including breast cancer and glioblastoma. Further research into predictive biomarkers and combination therapies is recommended for optimizing this CDK4/6 inhibitor.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Abemaciclib is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor.
  • Advanced solid cancers represent a significant unmet medical need.

Discussion:

  • Abemaciclib demonstrated antitumor activity across a range of advanced solid malignancies.
  • The findings support further investigation into abemaciclib's therapeutic potential in various cancer types.

Key Insights:

  • Abemaciclib exhibits preliminary efficacy in advanced breast cancer, glioblastoma, melanoma, non-small cell lung cancer, colorectal cancer, and ovarian cancer.
  • The drug's safety and pharmacokinetic/pharmacodynamic profiles were assessed.

Outlook:

  • Optimization of abemaciclib therapy may involve novel predictive biomarkers and rational combination strategies.
  • Future research should focus on refining treatment approaches for CDK4/6 inhibitor-responsive cancers.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K